Trial Profile
A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Patients (ELICE-BD)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Acronyms ELICE-BD
- 27 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Mar 2025.
- 27 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 01 Nov 2022 Planned End Date changed from 1 Dec 2022 to 31 Dec 2023.